CEL SCI Corp (CVM) shareholders
Close on Nov 16, 2026Market cap $29.20MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 555,000 | 6.94% | 13G (passive) | Aug 27, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CVM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 572,460 | 3.25% | $595.36K | +536,570 | 0.00% |
| Vanguard Capital Management LLC | 543,079 | 3.09% | $564.80K | +299,434 | 0.00% |
| Citadel Advisors LLC | 198,500 | 1.13% | $206.44K | New | 0.00% |
| MAI Capital Management | 108,280 | 0.62% | $112.61K | +17,000 | 0.00% |
| Geode Capital Management, LLC | 88,200 | 0.50% | $91.78K | +2,889 | 0.00% |
| Commonwealth Equity Services, LLC | 51,434 | 0.29% | $53.49K | +33,812 | 0.00% |
| Hrt Financial LP | 51,155 | 0.29% | $53.00K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 49,036 | 0.28% | $51.00K | – | 0.00% |
| BlackRock, Inc. | 43,261 | 0.25% | $44.99K | – | 0.00% |
| Bank Of America Corp /De/ | 40,916 | 0.23% | $42.55K | −81 | 0.00% |
| Jane Street Group, LLC | 36,458 | 0.21% | $37.92K | New | 0.00% |
| XTX Topco Ltd | 34,888 | 0.20% | $36.28K | +12,332 | 0.00% |
| Osaic Holdings, Inc. | 32,780 | 0.19% | $34.08K | +30,897 | 0.00% |
| US Bancorp \de\ | 29,907 | 0.17% | $31.10K | – | 0.00% |
| State Street Corp | 27,270 | 0.16% | $28.36K | – | 0.00% |
| Northern Trust Corp | 21,083 | 0.12% | $21.93K | +2,149 | 0.00% |
| Raymond James Financial Inc | 16,013 | 0.09% | $16.65K | New | 0.00% |
| Virtu Financial LLC | 11,315 | 0.06% | $12.00K | New | 0.00% |
| Financial Consulate, Inc | 10,000 | 0.06% | $10.40K | New | 0.00% |
| HighTower Advisors, LLC | 10,000 | 0.06% | $10.40K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 41 | 2M | 11.3% | 10 / 10 | 3 / 7 | 1M | 0M |
| Q1 2026 | 38 | 1M | 4.2% | 5 / 11 | 4 / 6 | 0M | 0M |
| Q4 2025 | 40 | 1M | 4.2% | 10 / 10 | 8 / 5 | 0M | 0M |
| Q3 2025 | 35 | 1M | 5.0% | 8 / 7 | 8 / 1 | 0M | 0M |
| Q2 2025 | 28 | 0M | 2.7% | 28 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held CVM in Q2 2026, 88% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CVM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 456,941 | 2.60% | $475.22K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 86,138 | 0.49% | $89.58K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 42,461 | 0.24% | $65.39K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,164 | 0.07% | $18.73K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 11,520 | 0.07% | $17.74K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 7,500 | 0.04% | $7.80K | 0.01% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 45 | 0.00% | $47 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Geert R. Kersten | Chief Executive Officer, Director | 630,310 | 3.58% | Oct 1, 2026 |
| Patricia B. Prichep | Chief Financial Officer | 19,571 | 0.11% | Oct 1, 2026 |
| Eyal Talor | Chief Scientific Officer | 10,483 | 0.06% | Oct 1, 2026 |
| John Cipriano | Senior Vice President | 63,108 | 0.36% | Aug 17, 2026 |
| Robert Eugene Watson | Director | 3,733 | 0.02% | Aug 17, 2026 |
| Bruno Jean-Marie Baillavoine | Director | 5,973 | 0.03% | Aug 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eyal Talor Chief Scientific Officer | Sep 30, 2026 | Award | +1,165 | $2.06 | $2.40K | 10,483 |
| Patricia B. Prichep Chief Financial Officer | Sep 30, 2026 | Award | +2,082 | $2.06 | $4.29K | 19,571 |
| Geert R. Kersten Chief Executive Officer, Director | Sep 30, 2026 | Award | +2,621 | $2.06 | $5.40K | 318,763 |
| Geert R. Kersten Chief Executive Officer, Director | Aug 25, 2026 | Buy | +100,000 | $1.38 | $138.00K | 316,142 |
| Geert R. Kersten Chief Executive Officer, Director | Jun 30, 2026 | Award | +5,192 | $1.04 | $5.40K | 216,142 |
| Eyal Talor Chief Scientific Officer | Jun 30, 2026 | Award | +2,307 | $1.04 | $2.40K | 9,318 |
| Patricia B. Prichep Chief Financial Officer | Jun 30, 2026 | Award | +4,125 | $1.04 | $4.29K | 17,489 |
| Geert R. Kersten Chief Executive Officer, Director | May 14, 2026 | Buy | +300,000 | $1.20 | $360.00K | 311,547 |
| Geert R. Kersten Chief Executive Officer, Director | May 13, 2026 | Buy | +100,000 | $1.19 | $119.00K | 222,497 |
| Eyal Talor Chief Scientific Officer | Mar 31, 2026 | Award | +747 | $3.21 | $2.40K | 7,011 |
| Patricia B. Prichep Chief Financial Officer | Mar 31, 2026 | Award | +1,336 | $3.21 | $4.29K | 13,364 |
| Geert R. Kersten Chief Executive Officer, Director | Mar 31, 2026 | Award | +1,682 | $3.21 | $5.40K | 122,497 |
| Geert R. Kersten Chief Executive Officer, Director | Jan 22, 2026 | Buy | +38,023 | $5.26 | $200.00K | 120,815 |
| Geert R. Kersten Chief Executive Officer, Director | Dec 31, 2025 | Award | +998 | $5.26 | $5.25K | 82,792 |
| Patricia B. Prichep Chief Financial Officer | Dec 31, 2025 | Award | +815 | $5.26 | $4.29K | 12,028 |
| Eyal Talor Chief Scientific Officer | Dec 31, 2025 | Award | +456 | $5.26 | $2.40K | 6,264 |
| Geert R. Kersten Chief Executive Officer, Director | Dec 4, 2025 | Buy | +8,389 | $5.96 | $50.00K | 81,794 |
| Geert R. Kersten Chief Executive Officer, Director | Sep 30, 2025 | Award | +570 | $9.20 | $5.24K | 73,405 |
| Patricia B. Prichep Chief Financial Officer | Sep 30, 2025 | Award | +466 | $9.20 | $4.29K | 11,213 |
| Eyal Talor Chief Scientific Officer | Sep 30, 2025 | Award | +260 | $9.20 | $2.39K | 5,808 |
| Robert Eugene Watson Director | Jul 25, 2025 | Buy | +2,919 | $6.85 | $20.00K | 3,733 |
| Geert R. Kersten Chief Executive Officer, Director | Jul 25, 2025 | Buy | +29,197 | $6.85 | $200.00K | 72,835 |
| Patricia B. Prichep Chief Financial Officer | Jun 30, 2025 | Award | +1,873 | $2.29 | $4.29K | 10,747 |
| Eyal Talor Chief Scientific Officer | Jun 30, 2025 | Award | +1,048 | $2.29 | $2.40K | 5,548 |
| Geert R. Kersten Chief Executive Officer, Director | Jun 30, 2025 | Award | +2,292 | $2.29 | $5.25K | 43,638 |
| Eyal Talor Chief Scientific Officer | Mar 31, 2025 | Award | +10,416 | $0.23 | $2.40K | 135,013 |
| Geert R. Kersten Chief Executive Officer, Director | Mar 31, 2025 | Award | +22,786 | $0.23 | $5.24K | 1,240,378 |
| Patricia B. Prichep Chief Financial Officer | Mar 31, 2025 | Award | +15,432 | $0.23 | $3.55K | 266,230 |
| Eyal Talor Chief Scientific Officer | Dec 31, 2024 | Award | +6,001 | $0.40 | $2.40K | 124,597 |
| Geert R. Kersten CEO, Director | Dec 31, 2024 | Award | +12,940 | $0.40 | $5.18K | 1,217,592 |
| Patricia B. Prichep Chief Financial & Operations | Dec 31, 2024 | Award | +10,727 | $0.40 | $4.29K | 250,798 |
| Geert R. Kersten Chief Executive Officer, Director | Sep 30, 2024 | Award | +4,882 | $1.06 | $5.17K | 1,204,652 |
| Eyal Talor Chief Scientific Officer | Sep 30, 2024 | Award | +2,264 | $1.06 | $2.40K | 118,596 |
| Patricia B. Prichep Sr. VP of Operations | Sep 30, 2024 | Award | +4,047 | $1.06 | $4.29K | 240,071 |
| Geert R. Kersten Chief Executive Officer, Director | Jun 28, 2024 | Award | +4,461 | $1.16 | $5.17K | 1,199,770 |
| Eyal Talor Chief Scientific Officer | Jun 28, 2024 | Award | +2,068 | $1.16 | $2.40K | 116,332 |
| Patricia B. Prichep Senior Vice President | Jun 28, 2024 | Award | +3,698 | $1.16 | $4.29K | 236,024 |
| Robert Eugene Watson Director | May 8, 2024 | Buy | +20,000 | $1.39 | $27.80K | 24,431 |
| Patricia B. Prichep Senior Vice President | May 8, 2024 | Buy | +8,000 | $1.39 | $11.12K | 232,326 |
| Geert R. Kersten Chief Executive Officer, Director | May 8, 2024 | Buy | +30,000 | $1.39 | $41.70K | 1,195,309 |
| Geert R. Kersten Chief Executive Officer, Director | Mar 29, 2024 | Award | +2,709 | $1.91 | $5.17K | 1,165,309 |
| Patricia B. Prichep Senior Vice President | Mar 29, 2024 | Award | +2,246 | $1.91 | $4.29K | 224,326 |
| Eyal Talor Chief Scientific Officer | Mar 29, 2024 | Award | +1,256 | $1.91 | $2.40K | 114,264 |
| Geert R. Kersten Chief Executive Officer, Director | Dec 29, 2023 | Award | +1,819 | $2.72 | $4.95K | 1,162,600 |
| Patricia B. Prichep Senior Vice President | Dec 29, 2023 | Award | +1,577 | $2.72 | $4.29K | 222,080 |
| Eyal Talor Chief Scientific Officer | Dec 29, 2023 | Award | +882 | $2.72 | $2.40K | 113,008 |
| Patricia B. Prichep Senior Vice President | Sep 29, 2023 | Award | +3,432 | $1.25 | $4.29K | 220,503 |
| Geert R. Kersten Chief Executive Officer, Director | Sep 29, 2023 | Award | +3,960 | $1.25 | $4.95K | 1,160,781 |
| Eyal Talor Chief Scientific Officer | Sep 29, 2023 | Award | +1,920 | $1.25 | $2.40K | 112,126 |
| Patricia B. Prichep Senior Vice President | Jun 30, 2023 | Award | +1,780 | $2.41 | $4.29K | 217,071 |
| Geert R. Kersten Chief Executive Officer, Director | Jun 30, 2023 | Award | +2,053 | $2.41 | $4.95K | 1,156,821 |
| Eyal Talor Chief Scientific Officer | Jun 30, 2023 | Award | +995 | $2.41 | $2.40K | 110,206 |
| Geert R. Kersten Chief Executive Officer, Director | Mar 31, 2023 | Award | +2,133 | $2.32 | $4.95K | 1,154,768 |
| Patricia B. Prichep Senior Vice President | Mar 31, 2023 | Award | +1,849 | $2.32 | $4.29K | 215,291 |
| Eyal Talor Chief Scientific Officer | Mar 31, 2023 | Award | +1,034 | $2.32 | $2.40K | 109,211 |
| Patricia B. Prichep Senior Vice President | Dec 30, 2022 | Award | +1,825 | $2.35 | $4.29K | 213,442 |
| Geert R. Kersten Chief Executive Officer, Director | Dec 30, 2022 | Award | +1,851 | $2.35 | $4.35K | 1,152,635 |
| Eyal Talor Chief Scientific Officer | Dec 30, 2022 | Award | +1,021 | $2.35 | $2.40K | 108,177 |
| Daniel H. Zimmerman Senior Vice President | Sep 30, 2022 | Award | +1,266 | $3.09 | $3.91K | 120,226 |
| Eyal Talor Chief Scientific Officer | Sep 30, 2022 | Award | +776 | $3.09 | $2.40K | 107,156 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cel Sci's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,997 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?